Novartis
NVS
NVS
903 hedge funds and large institutions have $18.2B invested in Novartis in 2016 Q4 according to their latest regulatory filings, with 121 funds opening new positions, 302 increasing their positions, 353 reducing their positions, and 80 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
2% less capital invested
Capital invested by funds: $18.7B → $18.2B (-$410M)
14% less repeat investments, than reductions
Existing positions increased: 302 | Existing positions reduced: 353
25% less funds holding in top 10
Funds holding in top 10: 28 → 21 (-7)
Holders
903
Holding in Top 10
21
Calls
$98.8M
Puts
$81.4M
Top Buyers
| 1 | +$186M | |
| 2 | +$156M | |
| 3 | +$151M | |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$135M |
| 5 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$131M |
Top Sellers
| 1 | -$176M | |
| 2 | -$59.7M | |
| 3 | -$36.4M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$36.3M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$34.2M |